Skip to main content
SpringerLink
Log in

Mantelzelllymphom und follikuläres Lymphom

  • Topic_Mantelzelllymphome
  • Published:
best practice onkologie Aims and scope

Das follikuläre Lymphom und das Mantelzelllymphom gehören nach der WHO Klassifikation zu den niedrig malignen Lymphomen. Besonders die Entität „Follikuläres Lymphom“ zeigt einen heterogenen, aber stets progredienten Verlauf – bei gutem Ansprechen auf Therapie – mit regelmäßigen Rezidiven und kürzer werdenden Remissionen. Das Mantelzelllymphom ist klinisch aggressiver. Bei beiden Erkrankungen hat der Einsatz des Anti-CD20-Antikörpers Rituximab die Therapie wesentlich verbessert. Weiterentwickelte CD20-Antikörper und „small molecules“ werden neue, chemotherapiefreie Therapieoptionen eröffnen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1 a–c
2 a–d
3
4
5
6

Literatur

  1. Herfarth K et al (2012) Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab: preliminary results of the mir trial. Phase II study of the German Low Grade Lymphoma Study Group (GLSG). 54h ASH Annual Meeting, Atlanta, Abstr 1634

    Google Scholar 

  2. Hiddemann W et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725–3732

    Article  CAS  PubMed  Google Scholar 

  3. Schulz H et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99: 706–714

    Article  CAS  PubMed  Google Scholar 

  4. Rummel MJ et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381: 1203–1210

    Article  CAS  PubMed  Google Scholar 

  5. Marcus R et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26: 4579–4586

    Article  CAS  PubMed  Google Scholar 

  6. Herold M et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25: 1986–1992

    Article  CAS  PubMed  Google Scholar 

  7. Salles G et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112: 4824–4831

    Article  CAS  PubMed  Google Scholar 

  8. Salles G et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377: 42–51

    Article  CAS  PubMed  Google Scholar 

  9. Lopez-Guillermo A et al (2013) A Randomized phase II study comparing consolidation with a single dose of 90y ibritumomab tiuxetan (Zevalin®) (Z) Vs. maintenance with rituximab ® for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R-CHOP. Preliminary results at 36 months from randomization. ASH: Abstr 369

    Google Scholar 

  10. Salles GA et al (2010) Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated nhl patients–updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL). Blood 116: 2868

    Google Scholar 

  11. Fowler NH et al (2012) Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study. ASH: Abstr 901

    Google Scholar 

  12. Fowler N et al (2012) The bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood 120 Abstr 156

    Google Scholar 

  13. Gopal A et al (2014) Mature response data from a phase 2 study Of PI3 K-delta inhibitor idelalisib in patients with double (Rituximab and Alkylating Agent)-refractory indolent B-Cell Non-Hodgkin Lymphoma (iNHL). N Engl J Med(epub ahead of print)

    Google Scholar 

  14. Davids MS et al (2013) Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 31 (Suppl): Abstr 8520

    Google Scholar 

  15. Hermine O et al (2012) Alternating curses of 3x CHOP and 3x DHAP plus rituximab followed by a high Dose ARA-C containing myeloablative regimen and Autologous Stem Cell Transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). ASH: Abstr 151

    Google Scholar 

  16. Hoster E et al (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell Lymphoma. Blood 114 (ASH Annual Meeting Abstracts): 880

    Google Scholar 

  17. Kluin-Nelemans HC et al (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367: 520–531

    Article  CAS  PubMed  Google Scholar 

  18. Hess G et al (2013) Temsirolimus added to bendamustin and rituximab (BERT): phase I results of a phase I/II-trial in patientswith relapsed follicular lymphoma (FL) and mantle cell lymphoma (MCL). Hematol Oncol 31: Abstr 149

    Google Scholar 

  19. Wang M et al (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13: 716–723

    Article  PubMed  Google Scholar 

  20. Wang M et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507–516

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik III Klinikum der Universität München-Großhadern, Marchioninistr. 15, 81377, München, Deutschland

    T. Seiler & M. Deyling

  2. Institut für Pathologie, Sektion für Hämatopathologie und Lymphknotenregister, Universität Kiel, Kiel, Deutschland

    W. Klapper

Authors
  1. T. Seiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Deyling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Klapper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Seiler.

Additional information

Einhaltung ethischer Richtlinien

Interessenkonflikt. T. Seiler gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seiler, T., Deyling, M. & Klapper, W. Mantelzelllymphom und follikuläres Lymphom. best practice onkologie 9, 6–13 (2014). https://doi.org/10.1007/s11654-013-0114-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-013-0114-5

Search

Navigation